When You Prescribe ENBREL, We're Here to Help
Support from your
ENBREL Access Specialist
We can help take the confusion out of insurance verifications and prior authorizations (IV/PAs).
Get assistance from your dedicated ENBREL Access Specialist (EAS) at 1-866-822-4680.
Looking for on-site support?
Your ENBREL Regional Access Specialist (ERAS) is ready to visit your practice.
Contact your ERAS today or call 1-888-4ENBREL (1-888-436-2735) to learn more.
Support from iAssist™
iAssist™ is a program designed to help streamline prior authorizations (PAs) and simplify the prescribing process.
- Identifies and autofills patient insurance information
- Allows you to ePrescribe ENBREL, along with any other therapies your patients are taking
- Provides the flexibility to submit PA forms online, either to payors, or directly to ENBREL Support™
- Includes submission tracking to review case history
Support, No Matter Their Situation
ENBREL Support™ offers financial assistance and options to help your patients afford treatment, regardless of insurance type.
First 6 months $0 out-of pocket costs per month
After 6 monts $10 or less out-of-packet costs per month
Patients can renew their enrollment for financial assistance every year. Limits apply.†
For your patients with commercial or private insurance, government insurance (like Medicare Part D or Medicaid), or no insurance at all, please call 1-888-4ENBREL.
* Eligibility Criteria: Open to patients with an ENBREL prescription and commercial insurance for ENBREL. Patients may not seek reimbursement for value received from the ENBREL Support™ Card from any third-party payers, including a flexible spending account or healthcare savings account. This program is not open to uninsured patients or patients receiving prescription reimbursement under any federal, state or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE or where prohibited by law. If at any time patients begin receiving prescription drug coverage under any such federal, state or government-funded healthcare program, patients will no longer be able to use this card and you must call ENBREL Support™ at 1-888-4ENBREL (8:00 AM-8:00 PM EST, Monday-Friday) to stop participation. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.
† Program Details: For all eligible patients, the ENBREL Support™ card program may offer: First 6 months at no out-of-pocket cost. After 6 months, $10 or less out-of-pocket per month. Each time patients fill their ENBREL prescription, they will receive 50% off their out-of-pocket costs or pay no more than $10 per month—whichever helps them more. Program provides up to $4,000 of assistance per patient for each 6-month period. Patient is responsible for costs above these amounts. Patients may use the card each time they fill their ENBREL prescription. Patients participation in the program may be renewed every 12 months by visiting EnbrelSupport.com or calling 1-888-4ENBREL.
Patient Tools and
In addition to offering financial support, ENBREL Support™ provides tools, resources, and practical support to your patients—all at no cost to them.
The ENBREL Starter Kit can help your patients get off to a good start. It's filled with information for new patients and includes a progress journal, convenient travel pack, and helpful magnetic calendar. Patients can find additional information at ENBREL.com.
Services to Keep Patients on Track
- Medication Reminders: Friendly opt-in injection and refill reminders, available via phone or e-mail, that help patients keep ENBREL on their schedules.
- Live Support from Nurses and Insurance Specialists: Patients can connect to a registered nurse, 7 days a week, 8 AM to 11 PM (ET), who can help to answer questions about injections, storing ENBREL, traveling with the medication, side effects, and more.
Prescription Enbrel® (etanercept) is administered by injection.
Please scroll to read Important Safety Information and Indications.
IMPORTANT SAFETY INFORMATION
Patients treated with Enbrel® (etanercept) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.
The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.
In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown.
Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.
Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.
In patients who initiated therapy at ≤ 18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin's and non-Hodgkin's lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.
Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.
CONGESTIVE HEART FAILURE
Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.
Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.
HEPATITIS B VIRUS REACTIVATION
Use of TNF blockers, including ENBREL, has been associated with reactivation of hepatitis B virus (HBV) in chronic carriers of this virus. The majority of these reports occurred in patients on concomitant immunosuppressive agents, which may also contribute to HBV reactivation. Exercise caution when considering ENBREL in patients identified as carriers of HBV.
Allergic reactions associated with administration of ENBREL during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.
Live vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin.
Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.
WEGENER'S GRANULOMATOSIS PATIENTS
The use of ENBREL in patients with Wegener's granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended.
MODERATE TO SEVERE ALCOHOLIC HEPATITIS
Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.
The most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials.
In a JIA study, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adult RA patients in placebo-controlled trials. The types of infections reported in JIA patients were generally mild and consistent with those commonly seen in outpatient pediatric populations.
The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.
Moderate to Severe Rheumatoid Arthritis (RA)
ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.
Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.
ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
Ankylosing Spondylitis (AS)
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
Moderate to Severe Rheumatoid Arthritis
In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.